Pfizer jab lowers infection risk by 93% in adolescents, Israelis find

Three-month study confirms Pfizer’s effectiveness against the deadly Delta variant

20 October 2021 - 23:02

The launch of vaccinations for 12- to 17-year-olds on Wednesday coincided with new findings that the Pfizer/BioNTech vaccine significantly decreases symptomatic Covid-19 in adolescents.

The three-month study in Israel, an early leader in Covid-19 vaccinations, involved almost 189,000 adolescents, equally split between vaccinated and unvaccinated...

This article is free to read if you register or sign in.

If you have already registered or subscribed, please sign in to continue.

Questions or problems? Email or call 0860 52 52 00.